ft 07 dec 93 uk compani news prescript futur growth glaxo set great store develop product last week dr richard syke glaxo chief execut spent tuesday afternoon sorcer room eleg thamesid hotel savoy object explain media first time nearli two year progress pipelin new product glaxo conjur futur compani europ largest drug group challeng world top posit current held merck us also offer round commerci environ prospect drug present emphasi research develop signific howev group go seduc diversif said dr syke reject strategi adopt group worldwid rationalis merger joint ventur merger gener counter non prescript busi instead glaxo adopt strategi concentr patent prescript medicin spite increasingli difficult environ drug group strategi focu rather dissip energi said dr syke plan maximis sale establish drug zantac anti ulcer treatment bring new innov drug market bring product market fast global basi invest develop market radic strateg departur adopt merck vertic integr dollar 6bn pound 4bn acquisit medco contain mail order compani also dismiss dr syke concept good doubt whether worth merck paid way achiev end less expens claim meanwhil glaxo adopt flexibl approach chang dr syke stress import react local condit commit local autonomi within framework central strateg direct also stress group annual report year sharp contrast manageri style dr ernest mario dr syke predecessor sack last march dr mario extrem detail grasp local condit understood meddl activ certain subsidiari key group abil maximis revenu remain abil increas revenu zantac best sell medicin time sale last financi year pound 2 2bn dr syke dismiss threat pose drug erad bacterium helicobact pylori associ ulcer patient effect treat zantac mainten therapi said dr syke patient take drug relaps good idea use combin drug erad hp agre erad hp everybodi come surgeri ulcer work anyth 10 per cent 70 per cent patient play russian roulett half peopl go relaps 10 per cent perfor 5 per cent die gambl like argu main threat zantac remain gener competit us patent tagamet smithklin beecham drug one zantac main competitor expir next year dr syke expect big impact direct relationship price usag servic volum discount drug offer equal import said dr syke meanwhil glaxo plan drive growth new product imigran migrain treatment zofran anti nausea drug serev asthma medicin glaxo increas manag flexibl demonstr decis launch low dose version imigran follow critic high price 100mg version dr syke said move launch 25mg 50mg dose would help expand market mild migrain although particularli driven critic price decis would help reduc meanwhil analyst believ develop pipelin look rich product compound exploratori develop 16 ever zofran also known ondansetron effect warner lambert cognex treatment alzheim symptom far safer said dr syke hope would file earli 1995 also highlight dr syke gr92132x treatment non insulin depend diabet glaxo hiv treatment 3tc also known lamivudin look effect hepat b huge killer develop world said ranitidin bismuth citrat could becom import hp erad use antibiot remifentanil inject anaesthet sleeper capabl becom import drug quip given compani full pipelin clear strategi base patent prescript medicin dr syke glaxo sorcer chief stake group futur abil creat market new drug glaxo sharehold must hope sorcer strategi turn hocu pocu glaxo full develop pipelin compound indic serev asthma use diskhal flixotid flovent asthma use diskhal flixotid flovent asthma use meter dose inhal flixotid flovent allergi 3tc aid lamivudin hepat b zofran post radiat emesi use tablet zofran opioid induc emesi use inject gr87442n chemotherapi radiat emesi use inject gr87442n chemotherapi radiat emesi use tablet gr87442n post oper nausea ondansetron dementia ondansetron anxieti remifentanil anaesthet analges gr92132x type 2 diabet ranitidin bismuth citrat duoden ulcer use tablet ranitidin bismuth citrat antibiot duoden ulcer ranitidin bismuth citrat gastric ulcer use tablet ranitidin bismuth citrat anti arthrit drug induc ulcer zantac gastric ulcer mainten zantac antibiot duoden ulcer zantac gastric ulcer mainten zantac anti arthrit drug induc ulcer imigran imitrex migrain tablet imigran imitrex cluster headach inject imigran migrain use effervesc imigran migrain use intranas devic imigran migrain use suppositori gr85548a migrain tablet compound intern new drug registr applic dossier serev approv 1h 94 flixotid flovent approv 2h 94 flixotid flovent approv 2h 94 flixotid flovent approv file 3tc 2h 94 2h 94 lamivudin 1996 1996 zofran approv file zofran 1h 95 1h 95 gr87442n 1996 1996 emesi use inject 1996 1996 gr87442n 1996 1996 emesi use tablet 1996 1996 gr87442n 1996 1996 ondansetron 1h 95 1h 95 ondansetron 2h 95 2h 95 remifentanil 1h 95 1h 95 gr92132x 1996 n ranitidin bismuth citrat 2h 94 2h 94 ranitidin bismuth citrat 2h 94 2h 94 ranitidin bismuth citrat 2h 94 96 ranitidin bismuth citrat 2h 94 2h 94 zantac approv 1h 94 zantac antibiot 2h 95 schedul zantac approv 1h 94 zantac n 1h 95 imigran imitrex approv file imigran imitrex approv file imigran 1h 94 2h 94 imigran 1h 95 1h 95 imigran 2h 95 1h 95 gr85548a 1996 1996